Table 2 Summary of trend in treatment of prostate cancer since the COVID-19 pandemic

Author, year	Baseline	Result	Measure	Period of interest (1)	Result	Period of interest (2)	Result
Sciarra 2020[26]	2019		Radical prostatectomy	2020	63.6% reduction
			Radiotherapy		84.6% reduction
Fallara 2021[19]	2017 to 2019	1,622	Radical prostatectomy	2020	1,574 (3% reduction)
		1,176	Radical radiotherapy		1,547 (32% increase)
		946	ADT		709 (25% reduction)
Ip 2021[17]	2018 to 2019	6,259	Radical prostatectomy	2019 to 2020	7,107	2020 to 2021	6,477
		2,419	Prostate fiducial markers		2,807		2,962
Pepe 2021[22]	2019 to 2020	54	Radical prostatectomy	2020 to 2021	39
		47	External radiotherapy		52
		pT3b: 11.2% nodal (+): 14.8 % metastatic: 5.9%	% of advanced, metastatic prostate cancer after prostatectomy		pT3b: 25.6% nodal (+): 46.1% metastatic: 9.3%
Nossiter 2022[24]	2019	5,331	Radical prostatectomy	2020	3,896 (26.9% reduction)
		11,309	Radical radiotherapy		9,719 (14.1% reduction)
		785	Brachytherapy		470 (40.1% reduction)
Deukeren 2022[25], odds ratio (95% CI)	Low-risk localized. intermediate-risk, localized, high-risk, or localized/locally advanced		Radical prostatectomy	2020 versus 2018 to 2019	1.32 (1.01 to 1.72)1.25 (1.07 to 1.47)1.16 (1.02 to 1.31)
Deukeren 2022[25], odds ratio (95% CI)	Low-risk localized. intermediate-risk, localized, high-risk, or localized/locally advanced		External beam radiotherapy and brachytherapy	2020 versus 2018 to 2019	1.09 (0.71 to 1.67)1.26 (1.05 to 1.51)0.99 (0.83 to 1.17)
			Brachytherapy		1.17 (0.80 to 1.72)0.63 (0.49 to 0.82)0.99 (0.83 to 1.17)
	Metastatic		ADT & radiotherapy		2.27 (1.77 to 2.91)

Abbreviations; ADT, androgen deprivation therapy; CI, confidence interval.